A Covid vaccine being manufactured in Scotland has reported a 90% immune response in early trials.
Biotech company Valneva tested its vaccine on 153 people and concluded it was safe and generally well tolerated.
The company will move to phase three by testing up to 5,000 people, some of whom will be recruited in Scotland.
UK Health Secretary Matt Hancock said if approved, the vaccine would play an "important role" in protecting communities.
Valneva, which manufactures its Covid vaccine at a plant in Livingston, said the results of their phase one/two study showed the vaccine was "highly immunogenic with more than 90% of all study participants developing significant levels of antibodies" to the Covid virus spike protein.
Those who received a medium dose of the vaccine showed an 89.8% immune response, while people given a high dose showed a 100% response.
The vaccine also induced T-cell responses, which help the body fend off a virus and play a role in long-lasting immunity.
No safety concerns were identified by an independent data safety monitoring board.
PUKmedia / BBC